Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6719470 | 0.88 | ALDH1A1 (0.57) | POLBGAAALDH1A1MAPTKMT2A | |
| SCHEMBL5142574 | 0.82 | POLB (0.76) | POLBGAAALDH1A1KMT2AMEN1 | |
| SCHEMBL8689405 | 0.81 | POLB (0.55) | POLBGAAALDH1A1MAPTKMT2A | |
| SCHEMBL307600 | 0.81 | POLB (0.74) | POLBGAAALDH1A1KMT2AMEN1 | |
| SCHEMBL31690894 | 0.81 | POLB (0.74) | POLBGAAALDH1A1KMT2AMEN1 | |
| SCHEMBL8691649 | 0.79 | ALDH1A1 (0.55) | POLBGAAALDH1A1MAPTKMT2A | |
| SCHEMBL26627737 | 0.79 | POLB (0.67) | POLBGAAALDH1A1KMT2AMEN1 | |
| SCHEMBL11620710 | 0.78 | POLB (0.73) | POLBGAAALDH1A1KMT2AMEN1 | |
| SCHEMBL5131103 | 0.78 | GAA (0.73) | POLBGAAALDH1A1KMT2AMEN1 | |
| SCHEMBL6718812 | 0.78 | ALDH1A1 (0.59) | POLBGAAALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
| WO-2004022534-A1 | ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS | NPS ALLELIX CORP. (CA) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | SLC1A2, SLC6A7, SLC1A1 | POLB 4182/4885GAA 136/4885ALDH1A1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.